RaviDRaoMD

Oncology • Fresno, CA

Physician

Join to view full profile

Dr. Rao is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Rao's full profile

Already have an account?

Office
7130 N Millbrook Ave
Suite 100
Fresno, CA 93720
Phone+1 559-447-4949

Fax+1 559-447-4950
Is this information wrong?

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2000 - 2004
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1997 - 2000
All India Institute of Medical SciencesClass of 1997

Certifications & Licensure

CA State Medical License 2008 - 2025
MN State Medical License 2000 - 2008
WI State Medical License 1998 - 2001
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Start of enrollment: 2004 Feb 01
Completed
Phase 3
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System Start of enrollment: 2004 Jan 01
Terminated
Phase 2
Everolimus in Treating Patients With Stage IV Melanoma Start of enrollment: 2005 Apr 01
Completed
Phase 2
Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2006 Oct 01
Completed
Phase 2
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery Start of enrollment: 2008 Jan 01
Completed
Phase 2
Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery Start of enrollment: 2008 Jan 01
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

Cancer Arising in a Duodenal Duplication Cyst: A Rare Genetic Anomaly.
Sarbjot Grewal, Neil Behniwal, Jasleen Kaur, Rupinder Mann, Ravi Rao> ;Cureus. 2021 Apr 30
Huffing and Puffing: A Rare Case of Tracheal Adenoid Cystic Carcinoma
Sarbjot Grewal, Namitha Malakkla, Jasleen Kaur, Pedram Ansari, Ravi Rao> ;Cureus. 2020 Dec 3
12 citations
Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance).
Jesus Vera Aguilera, Ravi D. Rao, Jacob B. Allred, Vera J. Suman, Harold E. Windschitl, Judith S. Kaur, William J. Maples, Val J. Lowe, Edward T. Creagan, Lori A. Eric...> ;The Oncologist. 2018 Aug 1
20 citations
Phase i study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors
Alan H. Bryce, Ravi D. Rao, Jann N. Sarkaria, Joel M. Reid, Yingwei Qi, Rui Qin, C. David James, Robert B. Jenkins, Joseph Boni, Charles Erlichman, Paul Haluska> ;Investigational New Drugs. 2012 Oct 1
Predictive factors for oligometastatic versus non-oligometastatic involvement of the central nervous system by brain metastases from breast cancer.
Garg S, Marsh JC, Rao RD, Griem KL> ;J. Clin. Oncol.. 2011-09-20
Comparison of Oncotype Dx (ODx) 21-gene recurrence score (RS) in African American (AA) and Caucasian (C) patients with hormone receptor-positive (HR+), HER2-negative (...
Kabaker KB, Canar J, Rao RD, Cobleigh MA> ;J. Clin. Oncol.. 2011-05-20
53 citations
Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious ...
Jann N. Sarkaria, Evanthia Galanis, Wenting Wu, Allan B. Dietz, Timothy J. Kaufmann, Michael P. Gustafson, Paul D. Brown, Joon H. Uhm, Ravi D. Rao, Laurence A. Doyle, ...> ;Clinical Cancer Research. 2010 Nov 15
119 citations
Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic
David A. Schomas, Nadia N. Laack, Ravi D. Rao, Fredric B. Meyer, Edward G. Shaw, Brian P. O'Neill, Caterina Giannini, Paul D. Brown> ;Neuro-Oncology. 2009 Aug 1
18 citations
Melanoma-induced brain metastases.
Robert R. McWilliams, Ravi D. Rao, Jan C. Buckner, Michael J. Link, Svetomir N. Markovic, Paul D. Brown> ;Expert Review of Anticancer Therapy. 2008 May 1
137 citations
Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3.
Ravi D. Rao, Patrick J. Flynn, Jeff A. Sloan, Gilbert Y. Wong, Paul J. Novotny, David B. Johnson, Howard M. Gross, Samer I. Renno, Mohammed Nashawaty, Charles L. Loprinzi> ;Cancer. 2008 Jun 15
257 citations
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
Ravi D. Rao, John C. Michalak, Jeff A. Sloan, Charles L. Loprinzi, Gamini S. Soori, Daniel A. Nikcevich, David O. Warner, Paul J. Novotny, Leila A. Kutteh, Gilbert Y. ...> ;Cancer. 2007 Nov 1
74 citations
The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism.
Charles L. Loprinzi, Kami Maddocks-Christianson, Sherry L. Wolf, Ravi D. Rao, P. James B. Dyck, Patrick W. Mantyh, Peter J. Dyck> ;Cancer Journal. 2007 Nov 1
3 citations
Vitamin e for the prevention of chemotherapy-induced peripheral neuropathy: rationale for an ongoing clinical trial.
Lisa A. Kottschade, Charles L. Loprinzi, Ravi D. Rao> ;Supportive Cancer Therapy. 2007 Sep 1
41 citations
Chemotherapy-induced neuropathy.
Anjali Bhagra, Ravi D. Rao> ;Current Oncology Reports. 2007 Jul 12
100 citations
Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment
Svetomir N. Markovic, Lori A. Erickson, Ravi D. Rao, Roger H. Weenig, Barbara A. Pockaj, Aditya Bardia, Celine M. Vachon, Steven E. Schild, Robert R. McWilliams, Jenni...> ;Mayo Clinic Proceedings. 2007 Apr 1
5 citations
Innovation in the management of brain metastases.
Ravi D. Rao, Paul D. Brown, Jan C. Buckner> ;Oncology. 2007 Apr 1
11 citations
Symptom control trials: a 20-year experience.
Charles L. Loprinzi, Debra L. Barton, Aminah Jatoi, Jeff A. Sloan, James A. Martenson, David P. Steensma, Ravi D. Rao, Paul J. Novotny, Amit Sood, Axel Grothey, Lori M...> ;The Journal of Supportive Oncology. 2007 Mar 1
269 citations
Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis
Svetomir N. Markovic, Lori A. Erickson, Ravi D. Rao, Robert R. McWilliams, Lisa A. Kottschade, Edward T. Creagan, Roger H. Weenig, Jennifer L. Hand, Mark R. Pittelkow,...> ;Mayo Clinic Proceedings. 2007 Mar 1
3 citations
Intratracheal Melanoma Metastases
Aditya Bardia, Ravi D. Rao> ;The New England Journal of Medicine. 2006 Sep 28
42 citations
Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Svetomir N. Markovic, Vera J. Suman, James N. Ingle, Judith S. Kaur, Henry C. Pitot, Charles L. Loprinzi, Ravi D. Rao, Edward T. Creagan, Mark R. Pittelkow, Jakob B. A...> ;American Journal of Clinical Oncology. 2006 Aug 1
Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma.
Rao RD, Windschitl HE, Allred JB, Lowe VJ, Maples WJ, Gornet MK, Suman VJ, Creagan ET, Pitot HC, Markovic SN> ;J. Clin. Oncol.. 2006-06-20
The efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: A phase III randomized, double blind, placebo-controlled NCCTG trial, N01C3.
Renno SI, Rao RD, Sloan J, Wong G, Johnson D, Howard GM, Novotny P, Patrick FJ, Loprinzi CL> ;J. Clin. Oncol.. 2006-06-20
Risk of multiple primary melanomas.
Aditya Bardia, Mark R. Pittelkow, Ravi D. Rao> ;JAMA. 2006 Apr 5
41 citations
Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response
Kurt A. Jaeckle, Karla V. Ballman, Ravi D. Rao, Robert B. Jenkins, Jan C. Buckner> ;Journal of Clinical Oncology. 2006 Mar 10
84 citations
Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma†‡
Ravi D. Rao, Shernan G. Holtan, James N. Ingle, Gary A. Croghan, Lisa A. Kottschade, Edward T. Creagan, Judith S. Kaur, Henry C. Pitot, Svetomir N. Markovic> ;Cancer. 2006 Jan 15
Join now to see all

Press Mentions

Cancer Patients Are Being Denied Drugs, Even with Doctor Prescriptions and Good InsuranceAugust 2nd, 2019
How the Shortage of a $15 Cancer Drug Is Upending TreatmentJune 27th, 2023